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Abstract
Background: The management of cartilage lesions is an open issue in clinical practice, and regenerative medicine
represents a promising approach, including the use of autologous micrografts whose efficacy was already tested in
different clinical settings. The aim of this study was to characterize in vitro the effect of autologous cartilage
micrografts on chondrocyte viability and differentiation and perform an evaluation of their application in
racehorses affected by joint diseases.
Materials and methods: Matched human chondrocytes and micrografts were obtained from articular cartilage
using Rigenera® procedure. Chondrocytes were cultured in the presence or absence of micrografts and chondrogenic
medium to assess cell viability and cell differentiation. For the pre-clinical evaluation, three racehorses affected by joint
diseases were treated with a suspension of autologous micrografts and PRP in arthroscopy interventions. Clinical and
radiographic follow-ups were performed up to 4 months after the procedure.
Results: Autologous micrografts support the formation of chondrogenic micromasses thanks to their content of matrix
and growth factors, such as transforming growth factor β (TGFβ) and insulin-like growth factor 1 (IGF-1). On the other
hand, no significant differences were observed on the gene expression of type II collagen, aggrecan, and
SOX9. Preliminary data in the treatment of racehorses are suggestive of a potential in vivo use of micrografts
to treat cartilage lesions.
Conclusion: The results reported in this study showed the role of articular micrografts in the promoting
chondrocyte differentiation suggesting their potential use in the clinical practice to treat articular lesions.
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Background
The management of cartilage lesions still represents a
challenge for surgeons, due to the limited regenerative
ability of cartilage, given its avascularity and hypocellular-
ity. Additionally, cartilage defects can lead to the patho-
genesis of osteoarthritis, resulting in pain and disability
with a high economic and social impact in many devel-
oped countries [1]. Depending on the type of cartilage de-
fect, different methodologies for cartilage repair and
regeneration can be applied today, such as arthroscopic
debridement [2], bone marrow stimulations [3], osteo-
chondral autografts, or allograft [4]. Beyond these meth-
odologies, autologous chondrocyte implantation (ACI) or
matrix-induced autologous chondrocyte implantation
(MACI) can represent valid approaches in the treatment
of cartilage defects, to promote the formation of hyaline
or hyaline-like cartilage and improve the pain and func-
tional outcomes in most of treated patients. However,
nowadays, the use of autologous chondrocytes is limited
by the need to perform two-stage procedures and by the
long recovery time required after surgery [5].
Recently, regenerative medicine approaches, based on
cell therapy or tissue engineering, gather increasing
interest, representing possible therapeutic alternatives.
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Indeed, the use of live cells with appropriate scaffold and
growth factors could allow for restoration of physio-
logical tissue within small or large defects. Nevertheless,
recent studies demonstrated that progenitors cells from
cartilage are the preferred cell type for this kind of
approach, since other cell types, such as bone
marrow-derived mesenchymal stem cells, are not able to
generate hyaline cartilage [6].
The Rigenera® procedure is an innovative clinical
protocol to obtain autologous articular micrografts,
containing both live cells and fragments of hyaline car-
tilage matrix, ready to use alone or in combination with
the most common scaffolds. Previous studies have been
reported that autologous micrografts are enriched of
progenitor cells and maintain regenerative properties
[7, 8]. The autologous micrografts are already used in
dentistry [9, 10]and wound healing [11–15], reporting
satisfactory results in terms of bone and dermal regen-
eration. Furthermore, some recent papers showed the
effectiveness of micrografts also in the cartilage and
cardiac regeneration [16, 17].
In this study, we provide an in vitro characterization
of cartilage autologous micrografts properties on chon-
drocytes viability and differentiation, together with an
evaluation of their pre-clinical application in racehorses
affected by joint diseases, where autologous micrografts
were used in combination with autologous platelet-rich
plasma (PRP) to better vehicle the micrografts in the in-
jured site and obtain a biocomplex ready to be used.
Joint diseases represent the main cause of reduced ath-
letic function for racehorses and are characterized by a
degenerative process involving several components of
the joints including cartilage, subchondral bone, and ar-
ticular capsule [18]. Anti-inflammatory and analgesic
drugs represent the standard treatment for mild defects,
while articular cartilage curettage, osteophyte removal or
surgical arthroscopy, and arthrodesis can be indicated
for severe cartilage and bone degeneration [19]. Never-
theless, while all these therapies effectively reduce symp-
toms, they are not able to restore the physiological
conditions in cartilage tissue. Regenerative therapy for
racehorses is assuming a growing interest for the signifi-
cant economic impact on the horse industry, and race-
horses can be a valuable large animal model for the
evaluation of new therapies due to the interspecies simi-
larities with humans in the thickness of the non-calcified
cartilage of the stifle joint [20].
Materials and methods
Isolation of human primary chondrocytes and culture
with micrografts
Human primary chondrocytes were isolated from eight
samples of articular cartilage of femoral head of donor pa-
tients undergoing total hip arthroplasty. All individuals
provided informed consent as per the Institutional Review
Board approved procedure (M-SPER-014.ver7). Primary
chondrocytes were isolated from articular cartilage (0.6–
1.2 mg) using overnight incubation at 37 °C with 0.15% w/
v type II collagenase (Worthington, NJ, USA) solution in
DMEM (Sigma Aldrich, MO, USA) + 5% fetal bovine
serum (FBS, Hyclone, Thermo-Fisher Scientific, MA,
USA). Cells were then seeded at 5.000 cell/cm2 for expan-
sion. The autologous micrografts were obtained by Rigen-
era protocol after mechanical disaggregation using a
medical disposable Rigeneracons (Human Brain Wave srl,
Turin, Italy) [9]. Briefly, 200 mg of each sample was
inserted in the Rigeneracons and minced for 5 min in a
total of 5 ml of DMEM. The primary chondrocytes
isolated by collagenase were cultured in four different
conditions: DMEM supplemented with 10% FBS (control
medium), control medium plus 10% v/v autologous
micrografts, DMEM supplemented with 1% FBS and
chondrogenic factors (chondrogenic medium), and chon-
drogenic medium plus 10% v/v autologous micrografts.
For cell viability assay, only control medium and control
medium with 10% v/v autologous micrografts were tested.
Particles obtained after disaggregation with Rigenera
ranged from 50 to 70 μm.
Cell viability
Cell viability was assessed at 1, 4, 7, and 14 days of incuba-
tion with the different media by MTT [3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide, Sigma-Aldrich]
assay. Cells at passage 3 were cultured in 96-well plates at
the density of 3.0 × 103 cells/cm2; to perform the assay, a
final concentration of 0.5 mg/mL MTT was added to the
culture medium and incubated for 4 h at 37 °C; the
medium was removed and 100% DMSO was added to each
well to solubilize the precipitate. Absorbance was read at
570 nm.
Chondrogenetic differentiation assay
For chondrogenic differentiation, 5.0 × 105 cells were
centrifuged at 250g for 5 min to obtain pellets. The pel-
lets were cultured in four different media: control
medium, DMEM supplemented with 100 U/ml penicil-
lin, 100 μg/ml streptomycin, 0.29 mg/ml L-glutamine,
1 mM sodium pyruvate, 1.25 mg/ml human serum albu-
min (HAS; Sigma-Aldrich), and 10% FBS; chondrogenic
medium, consisting of DMEM supplemented with
100 U/ml penicillin, 100 μg/ml streptomycin, 0.29 mg/
ml L-glutamine, 1 mM sodium pyruvate, 1.25 mg/ml hu-
man serum albumin (HAS; Sigma-Aldrich), 1% ITS+1
containing 1.0 mg/ml insulin from bovine pancreas,
0.55 mg/ml human transferrin, 0.5 μg/ml sodium selen-
ite, 50 mg/ml bovine serum albumin and 470 μg/ml
linoleic acid (Sigma-Aldrich), 0.1 μM dexamethasone,
0.1 mM L-ascorbic acid-2-phosphate, and 10 ng/ml
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TGF-β1 (PeproTech, Rocky Hill, NJ, USA) (Lopa S);
control medium plus 10% v/v autologous micrografts;
chondrogenic medium plus 10% v/v autologous micro-
grafts. The medium was replaced every 3 days and cells
cultured at 37 °C under a 5% CO2 atmosphere for
4 weeks before the following evaluations.
Histology and immunohistochemistry
For the histological analysis, representative pellets from
each sample and treatment (n = 32) were fixed in 10%
neutral buffered formalin (Bio-Optica Milano SpA,
Milan, Italy), embedded in paraffin blocks, and cut into
4-μm-thick sections. To detect sulfated glycosaminogly-
cans (GAGs), sections were stained with standard Alcian
blue protocol (Bio-Optica). Briefly, slides were deparaffi-
nized and rehydrated then stained with Alcian blue
(pH 2.5; according to Mowry) for 30 min. The sections
were then immersed in a sodium tetraborate solution for
10 min and counterstained with Mayer’s hematoxylin,
dehydrated, and mounted.
For immunohistochemical localization of collagen type
I (COLL I) and collagen type II (COLL II), the sections
were dewaxed and rehydrated, and a heat-induced anti-
gen retrieval was applied using a microwave treatment
for 5 min at 400 W in citrate buffer pH 6.0 (Thermo
Fisher Scientific, Waltham, MA, USA). Then, the slides
were treated with 3% H2O2 in absolute methanol for
10 min to quench endogenous peroxidases and succes-
sively with 3% w/v bovine serum albumin (BSA) in PBS
for 30 min to inhibit non-specific reactivity. Biotinylated
anti-COLL I (10 μg/ml; #7026, Chondrex Inc., Redmond,
WA, USA) and biotinylated anti-COLL II (10 μg/ml;
#7049, Chondrex Inc.) antibodies were applied overnight
at 4 °C in a humid chamber upon sections. The primary
antibodies were diluted in PBS with 1% w/v BSA and 0.3%
v/v Tween 20 (Thermo Fisher Scientific). At the end of in-
cubation, biotinylated antibodies were detected with strep-
tavidin conjugated to horseradish peroxidase (Abcam,
Cambridge, UK) and then with HIGHDEF® yellow IHC
chromogen (Enzo Life Sciences Inc., Farmingdale, NY,
USA). All sections were finally weakly counterstained with
Mayer’s hematoxylin, dehydrated, and mounted. For nega-
tive control, the primary antibody was omitted. Photomi-
crographs were taken with an Olympus IX71 light
microscope and an Olympus XC10 camera (Japan).
GAGs deposition
Glycosaminoglycans (GAG) content was evaluated by
dimethylmethylene blue (DMMB) assay. Briefly, the pel-
lets were digested at 60 °C for 16 h in PBE buffer
(100 mM Na2HPO4, 10 mM Na EDTA, pH 6.8) con-
taining 1.75 mg/ml L-cysteine (Sigma-Aldrich) and
14.2 U/ml papain (Worthington, Lakewood, NJ, USA).
The obtained extracts were incubated with 16 mg/l
dimethylmethylene blue (Sigma-Aldrich), and absorb-
ance was read at 500 nm (Perkin Elmer Victor X3 mi-
croplate reader). For normalization purposes, DNA
content evaluation was performed on each sample by
CyQUANT Kit (Life Technologies), following manufac-
turer’s instructions. Data are presented as microgram of
GAGs per microgram of DNA.
Quantitative real time-PCR
Total RNA was isolated from cells using TriReagent
(Life Technologies) and cDNA was synthesized from
1 μg of total RNA by reverse transcription (RT) reaction.
The expression of type II collagen (COL2A1), SOX9, and
aggrecan (ACAN) mRNAs was measured by real-time
RT-PCR, using TaqMan reagents (Life Technologies).
The calculations of the results were carried out accord-
ing to the 2ΔCt methods. GAPDH was used as an in-
ternal control for data normalization [21].
Growth factors measurement
Immediately after micrograft production with the
Rigenera protocol, an aliquot of the micrograft suspen-
sion was frozen at − 20 °C. Transforming growth factor
β (TGFβ) and insulin-like growth factor 1 (IGF-1) con-
centrations in the micrograft suspensions were measured
by commercially available ELISA kit, according to the
manufacturer’s instructions (Peprotech, UK).
Horses
Three horses (1 gelding and 2 thoroughbreds) aged from
3 to 5 years (4.4 ± 1.5) with intra-articular lesions were
treated. Their characteristics, before and after treatment,
are provided in Table 1.
Preparation of equine platelet-rich plasma (PRP)
Autologous PRP was prepared as previously described
[22]. Briefly, two units of 450 ml of blood are collected
from the horses through a standard triple-bag system, a
method that allows easily the removal of 450–900 ml of
blood. Sampling was done from the jugular vein after
trichotomy and disinfection of the area. Blood was cen-
trifuged at 1450 rpm for 10 min at 20 °C, in order to ob-
tain the separation of red blood cells from plasma
containing platelets and the factors that lead to the for-
mation of a clot. Plasma is then centrifuged at 3000 rpm
for 20 min at 20 °C, thus obtaining the separation of a
platelet pellet and platelet-poor plasma (PPP). The plate-
lets are then re-suspended in 30–35 ml of PPP in order
to have a PRP with a platelet concentration of about 1 ×
106 platelets/μl. The bag containing the PRP is placed
on a platelet agitator under constant agitation at room
temperature and after about 2 h transferred under a
sterile hood to dispense the platelet concentrate into
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sterile tubes (Monovette, Sarstedt). The PRP product is
stored at − 20 °C until use.
Use of equine autologous micrografts and PRP in
arthroscopy interventions
Equine autologous micrografts were prepared as previ-
ously described using Rigenera protocol. Briefly, a small
piece of intra-articular cartilage (weight 0.0230 g) was col-
lected by endoscopic procedure and disaggregated by
Rigeneracons medical device for 5 min for three times
adding 1.5 ml of sterile physiological solution (Fig. 1a–d).
The chondrocyte-derived micrografts were then mixed to
10 ml of PRP (Fig. 1d) and after an arthroscopic curettage
injected in the articular lesions of horses (Fig. 1e). After
the procedure, the skin is disinfected with iodine product
and dressed with cotton gauze and a Vetrap-type bandage
strip. The dressing remains in situ for 48 h. A clinical
follow-up was performed every week, while the radio-
graphic follow-up was performed between 4 and 6 months
after arthroscopy.
Statistical analysis
All data are reported as means ± SD. Statistical differ-
ence between two groups was determined by one-way
ANOVA or t test, when appropriate. The significance
was established for a p value ≤ 0.05.
Results
Effect of autologous micrografts on chondrocyte
differentiation and viability
The effect of micrografts on cell viability was evaluated
after 10 days of culture, and no significant interference
Table 1 Baseline characteristics of horses before and after treatment
Horses Sex and breed Diagnosis AAEP lameness scale
(before treatment)
AAEP lameness scale
(after treatment)
1 Gelding, quarter horse Middle-carpal joint arthrosis, severe cartilage erosions, and detachment
on radial and third carpal bone, radial bone fragments
3 0
2 Male, thoroughbred Severe cartilage damage to the metacarpal-phalangeal joint, joint space
reduction, early signs of bone proliferation associated with degenerative
osteoarthritis at early stage
3 0
3 Female, thoroughbred Cartilage ulcer of the dorsomedial eminence of the first phalanx. Linear
erosions of metacarpal condyles. Cartilage thinning
2 1
AAEP American Association of Equine Practitioners
Fig. 1 Collection of equine autologous micrografts. a, b During the arthroscopy intervention, a small piece of intra-articular cartilage was collected
by endoscopic procedure. c, d The intra-articular cartilage was inserted in Rigeneracons disposable and disaggregated for 2 min by a rotation process
triggered by Rigenera machine. e, f The micrografts obtained were mixed to autologous PRP and directly injected on the lesion
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was observed comparing cells cultured in the presence
and absence of cartilage micrografts (Fig. 2a). The chon-
drocyte differentiation was evaluated by histology and
immunohistochemistry on human primary chondrocyte
pellets cultured in the presence or absence of autologous
micrografts. The micromasses cultured in the presence
of micrografts showed higher dimension and positivity
to Alcian blue staining with respect to control samples.
When cultured in a chondrogenic medium, these differ-
ences were less obvious, but the action of micrografts in
favoring cell harboring was confirmed (Fig. 2b). In
addition, a DMMB assay revealed that GAGs content
was significantly increased in the cells cultured with
micrografts in standard culture conditions (p < 0.01)
Fig. 2 Chondrogenic differentiation. a Cell viability evaluated after 10 days of culture in the presence or absence of autologous micrografts. The
results are expressed as fold increase with respect to chondrocytes cultured without micrografts (= 1). b Alcian blue staining to evaluate the
chondrogenic differentiation of cells cultured in the control or chondrogenic medium with or without autologous micrografts (magnification ×
20). c GAGs deposition in cells cultured in the control or chondrogenic medium with or without autologous micrografts (**p < 0.01, ***p < 0.001
vs cells in the control medium without micrografts; ## p < 0.01 vs cells in the chondrogenic medium without micrografts)
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(Fig. 2c). Nevertheless, a decrease was observed in chon-
drogenic medium plus micrografts cultured pellets with
respect to samples maintained in chondrogenic medium
alone. Despite this difference resulted statistically signifi-
cant (p < 0.01), the differentiation ability was not pre-
vented as demonstrated by the great increase in GAGs
content observed in these pellets when compared to
control cells (p < 0.001) (Fig. 2c).
Finally, immunohistochemistry analysis revealed a
strong presence of type II collagen in the chondrocytes
plus micrografts with respect to those without micro-
grafts, both in the control or chondrogenic medium
(Fig. 3). As expected, the cells are negative for type I colla-
gen (Fig. 4), confirming the lack of trans-differentiation
events.
Evaluation of the cartilage-specific gene expression
Type II collagen and aggrecan are critical components
for cartilage structure. We evaluated their expression in
human primary chondrocytes showing that in the chon-
drogenic medium, the expression of these markers in-
creases with respect to samples cultured in control
medium, in the presence or absence of autologous
micrografts. The expression of the cartilage-specific
transcription factor SOX9 resulted more expressed in
samples treated with chondrogenic medium and micro-
grafts, with respect to all the other culture conditions.
Nevertheless, due to the high inter-donor variability, no
statistically significant differences were found in the gene
expression of these markers (Fig. 5a–c).
Autologous micrografts suspension contains cartilage
trophic factors
The suspension of the autologous micrografts was
assayed for cartilage trophic factors TGFβ and IGF-1.
The mean content of TGFβ in all micrografts samples
was 81.4 ± 88.2 pg/ml, while IGF-1 was 676.3 ± 212.7 pg/
ml. All samples showed the presence of IGF-1, while
only six out of eight samples showed the presence of
TGFβ (Fig. 5d).
Use of autologous micrografts plus PRP for arthroscopic
intervention in the sport racehorses
Autologous micrografts and PRP were used for arthro-
scopic intervention in sports racehorses affected by joint
disease causing lameness. In the first horse, a severe car-
tilage erosion was observed (Fig. 6a) and the RX
pre-intervention showed the presence of both middle-
carpal arthrosis and an osteophyte on the dorsomedial
edge of the radial bone with an articular fragment close
to the third carpal bone (Fig. 6b). After 4 months from
intervention, an improvement of articular, dorsomedial,
and inter-carpal edge can be observed (Fig. 6c). In the
second horse, a severe cartilaginous damage was
observed (Fig. 6d) and the RX pre-intervention showed a
reduced articular space and an early stage of degenera-
tive arthrosis (Fig. 6e). After 4 months from micrografts
plus PRP injection, an increase of articular and
peri-articular proliferation was observed (Fig. 6f ). For
the third horse, the diagnosis of cartilagenous damage
on the fetlock was confirmed by clinical evidences but
not at a radiographic level showing no difference before
and after the treatment (data not shown). In two cases, a
complete resolution of lameness which allowed the
recovery of sports race activity was observed
(Additional files 1 and 2).
Discussion
The possibility to use biological strategies to enhance
the cartilage regeneration ability in a one-step surgery
would represent an important advance in the treatment
of cartilage defects. Indeed, while the most used tech-
niques are nowadays limited to microfractures for bone
marrow stimulation or two-step surgeries for articular
chondrocyte transplantation, the use of Rigenera® pro-
cedure would improve the feasibility of biological treat-
ments in the field. The in vitro results reported in this
study demonstrate that autologous micrografts do not
affect chondrocyte viability and influence chondrocyte
differentiation, as shown by both increased GAGs depos-
ition and the presence of collagen II in primary human
cells cultured in the presence of micrografts supporting
the formation of chondrogenic micromasses and acting
like a scaffold for chondrocyte harboring. From our ex-
periments, the presence of IGF-1 and TGFβ in the prod-
uct obtained by cartilage processing with Rigenera
protocol also emerged; both factors were able to en-
hance cartilage repair in vivo by increasing proteoglycan
synthesis and stimulating mesenchymal stem cell differ-
entiation into chondrocytes, stimulate matrix synthesis,
and reverse the catabolic effects of pro-inflammatory
cytokines [23, 24].
Previous in vitro studies reported that micrografts
maintained a high cell viability after mechanical disag-
gregation of different types of human tissues such as
dental pulp, periosteum, and cardiac atrial appendage [7]
and that they are able to differentiate in osteocytes, adi-
pocytes, and chondrocytes [8].
In addition to in vitro data, the study provides positive
preliminary results in the treatment of racehorses af-
fected by joint diseases, suggesting an in vivo application
of cartilage micrografts associated with PRP. The efficacy
of micrografts in the cartilage repair was reported in
previous human studies where the authors described the
combined the use of autologous chondrocyte-derived
micrografts and PRP to reconstruct not hyaline alar
nasal cartilage and to promote cartilage regeneration in
patients affected by external nasal valve collapse. In fact,
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the constructs of chondrocyte micrografts-PRP re-
sulted in a persistent cartilage tissue with appropriate
morphology, adequate central nutritional perfusion
without central necrosis or ossification, and further
augmented nasal dorsum without obvious contraction
and deformation [16, 25].
To confirm the clinical efficacy of micrografts in the tis-
sue repair/regeneration, several case series studies were
performed in different clinical areas such as dentistry,
dermatology, and wound care. To this regard, it has been
reported that human dental pulp or periosteum-derived
micrografts were able to promote the bone regeneration
in the atrophic maxilla [9], to preserve the alveolar socket
after tooth extraction by both reducing bone resorption
and increasing new bone formation [10] and to promote
sinus lift augmentation [26]. Autologous micrografts also
improve the wound healing of complex post-operative and
post-traumatic wounds [27] of post-surgical dehiscences
Fig. 3 Type II collagen expression. The type II collagen expression was evaluated by immunohistochemistry in the cells cultured both in the
control or chondrogenic medium in the presence or absence of autologous micrografts after 4 weeks of culture (magnification × 10 and × 20)
Viganò et al. Journal of Orthopaedic Surgery and Research          (2018) 13:279 Page 7 of 12
[11, 12] and chronic ulcers [13, 14]. Furthermore, micro-
grafts were also used in the treatment of pathological
and hypertrophic scars restoring the structural layers
immediately below the epidermis and promoting the
horizontal realignment of collagen fibers in the papil-
lary dermis [15]. Finally, a very recent paper showed
the ability of autologous micrografts to induce cardiac
regeneration [17].
Joint healing can be improved by supplying stem cells,
growth factors, and growth substrates at the site of in-
jury. For example, several studies demonstrate that mes-
enchymal stem cells were effective in the bone and
cartilage regeneration due their capacity to differentiate
into osteocytes and chondrocytes and stimulate the syn-
thesis of the chondrocyte extracellular matrix [28]. In
previous studies, we showed that cells contained in the
Fig. 4 Type I collagen expression. The type I collagen expression was evaluated by immunohistochemistry in the cells cultured both in the
control or chondrogenic medium in the presence or absence of autologous micrografts after 4 weeks of culture (magnification × 10 and × 20)
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Fig. 5 Gene expression of ACAN, COL2, and SOX9 and measurement of cartilage trophic factors TGFβ and IGF-1. a–c mRNA expression of ACAN
(aggrecan), COL2 (type II collagen), and SOX9 was evaluated in the cells cultured both in the control or chondrogenic medium in the presence or
absence of autologous micrografts after 4 weeks of culture. The results are expressed as dCt vs. GAPDH. d The levels of cartilage trophic factors
TGFβ and IGF-1 were measured by ELISA in the autologous micrografts suspension. *p < 0.05, **p < 0.01 vs control medium (−) micrografts;
##p < 0.01 vs control medium (+) micrografts
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micrografts derived from different tissues express mesen-
chymal stem cells (MSCs) markers, such as CD90, CD73
and CD105, CD117, and CD44 [7, 8, 25], suggesting the
presence of MSCs or tissue-specific progenitors within
micrografts, as a possible explanation of their regenerative
potential. Behind the stem cells, also the PRP containing
both PDGF and TGF-β1 was shown to be effective in car-
tilage regeneration by promoting chondrocyte prolifera-
tion and synthesis of proteoglycan and type II collagen
[29]. We reported in this study the pre-clinical application
of autologous micrografts combined with PRP in the car-
tilage repair in racehorses, suggesting that a combined ac-
tion of both these factors would be able to promote the
osteochondral regeneration. In fact, PRP alone resulted ef-
fectively in the treatment of cartilage lesions only at
short-term [30, 31], and it has been suggested that the
combination with other approaches would allow for the
stabilization of its beneficial effects [29]. Even if the known
short-term effect of PRP may have masked the benefits of
autologous cartilage micrografts, our in vivo data provide
the first proof of concept for the use of the combination
of these techniques in cartilage defects. Moreover, the use
of osteochondral autografts and allograft is already a
well-established practice in the management of horse in-
juries, allowing the treatment of large defects, thanks to
the immediate reconstruction of the articular surface by
transfer of mature intact hyaline cartilage and the under-
lying subchondral bone. The success of this technique de-
pends on the viability of chondrocytes in the graft and on
the mechanical stability of the host–graft interface [32].
Furthermore, the use of osteochondral grafts transfer is
limited by donor site availability in the autologous ap-
proach or joint congruency and host response in the case
of allogeneic tissue [19]. The use of autologous micro-
grafts overcomes some of these limitations, given that
their collection is scarcely invasive, reducing donor site
morbidity without influencing the grafts viability and over-
coming the possible rejection issue related to allogeneic
grafts.
Conclusion
Taken together, these results showed that autologous
cartilage micrografts may promote cartilage repair,
favoring chondrocytes harboring and growth, and
Fig. 6 Application of equine autologous micrografts in arthroscopy intervention. a Endoscopic image of left intercarpal joint showing the surface
of the radial bone of the carpus after curettage and removal of the large portion of damaged cartilage. b, c Right front carpus, dorsolateral
palmaro-medial X-ray pre- and post-intervention which evidences the radio-carpal joint, the middle carpal joint, and the proximal extremities of
the metacarpal bones. Osteophyte on the dorsomedial edge of radial bone (yellow arrow) and articular fragment close to the third carpal bone
(red arrows). d Endoscopic image of right metacarpal-phalangeal joint showing a severe damage to the articular cartilage. At the bottom, at the
level of the lateral condyle of third metacarpal bone, and at the top, on the lateral portion of the proximal side eminence of the phalanx. e, f
Right fetlock, dorsolateral palmaro-medial X-ray pre- and post-intervention which reports the metacarpal-phalangeal joint. Articular space and
signs of bone proliferation before and after treatment (red arrows)
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they suggest their potential in the treatment of
articular lesions in combination with PRP. However,
further studies are needed to confirm the effec-
tiveness of micrografts on cartilage repair/regener-
ation both alone or in combination with different
approaches.
Additional files
Additional file 1: Resolution of lameness after micrograft application.
Videos showing the activity of horses 1 and 3 (referring to Table 1) after
4 months from micrografts application. (MP4 2050 kb)
Additional file 2: Resolution of lameness after micrograft application.
Videos showing the activity of horses 1 and 3 (referring to Table 1) after
4 months from micrografts application. (MP4 10901 kb)
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